Evidence map›Paper›PMID 27044752›Full record

ArticleThe Journal of biological chemistry2016

Molecular Mechanism of Regulation of MTA1 Expression by Granulocyte Colony-stimulating Factor.

Arathy S Kumar, Sankar Jagadeeshan, Anirudh Subramanian, Saravana Babu Chidambaram, Rohan Prasad Surabhi, Mahak Singhal, Hemadev Bhoopalan, Sathiya Sekar, Ravi Shankar Pitani, Prathiba Duvuru and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Analysis ofBioMed research international · 2023
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Arathy S KumarFrom the Department of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai 600 036 and.
Sankar JagadeeshanFrom the Department of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai 600 036 and.
Anirudh SubramanianFrom the Department of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai 600 036 and.
Saravana Babu Chidambaramthe Centre for Toxicology and Developmental Research (CEFT).
Rohan Prasad SurabhiDepartments of Human Genetics.
Mahak SinghalFrom the Department of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai 600 036 and.
Hemadev BhoopalanDepartments of Human Genetics.
Sathiya Sekarthe Centre for Toxicology and Developmental Research (CEFT).
Ravi Shankar PitaniCommunity Medicine, and.
Prathiba DuvuruPathology, Sri Ramachandra University, Porur, Chennai 600 116, India.
Ganesh VenkatramanDepartments of Human Genetics, ganeshv@sriramachandra.edu.in.
Suresh K RayalaFrom the Department of Biotechnology, Indian Institute of Technology Madras (IITM), Chennai 600 036 and rayala@iitm.ac.in.
Sri Ramachandra Institute of Higher Education and Research · INIndian Institute of Technology Madras · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson disease (PD) is a neurodegenerative disorder with loss of dopaminergic neurons of the brain, which results in insufficient synthesis and action of dopamine. Metastasis-associated protein 1 (MTA1) is an upstream modulator of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis, and hence MTA1 plays a significant role in PD pathogenesis. To impart functional and clinical significance to MTA1, we analyzed MTA1 and TH levels in the substantia nigra region of a large cohort of human brain tissue samples by Western blotting, quantitative PCR, and immunohistochemistry. Our results showed that MTA1 and TH levels were significantly down-regulated in PD samples as compared with normal brain tissue. Correspondingly, immunohistochemistry analysis for MTA1 in substantia nigra sections revealed that 74.1% of the samples had a staining intensity of <6 in the PD samples as compared with controls, 25.9%, with an odds ratio of 8.54. Because of the clinical importance of MTA1 established in PD, we looked at agents to modulate MTA1 expression in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen, due to its clinically proven neurogenic effects. Treatment of the human neuronal cell line KELLY and acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model with G-CSF showed significant induction of MTA1 and TH with rescue of phenotype in the mouse model. Interestingly, the observed induction of TH was compromised on silencing of MTA1. The underlying molecular mechanism of MTA1 induction by G-CSF was proved to be through induction of c-Fos and its recruitment to the MTA1 promoter.

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsBlotting, WesternCell Line, TumorDopamineDopamine AgentsGene ExpressionGranulocyte Colony-Stimulating FactorHistone DeacetylasesHumansImmunohistochemistryMaleMice, Inbred C57BLMotor ActivityNeuronsParkinson Disease1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineDopamineDopamine AgentsGranulocyte Colony-Stimulating FactorHistone DeacetylasesMTA1 protein, humanRepressor ProteinsTrans-ActivatorsTyrosine 3-Monooxygenasedopaminegrowth factornuclear receptorParkinson diseasetranscription coregulator

Identifiers

PMID27044752
PMCPMC4933278
OpenAlexW2415612875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.